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ReperfusionIt is believed that the diabetic myocardium is refractory to cardioprotection by ischemic preconditioning (IPC)
mainly because of impaired insulin signaling to phosphatidylinositol 3-kinase (PI3K) and protein kinase B
(PKB or Akt). However, human as well as animal studies have clearly showed that the hearts of type 2 diabetic
humans and animals may exhibit increased signaling through PI3K–Akt but yet are resistant to cardioprotection
by IPC or ischemic post-conditioning. Therefore, this study was designed to determine whether activation of in-
sulin signaling prior to IPC is detrimental for cardioprotection and to assess the role of insulin receptors (IRs) and
Akt inmediating this effect. Wild-type (WT) hearts, hearts lacking IRs or hearts expressing an active form of Akt
(myrAkt1) were perfused ex vivo using a Langendorff preparation and were subjected to IPC (3 cycles of 5 min
ischemia followed by 5 min reﬂow before 30 min no ﬂow ischemia and then by 45 min reperfusion) in the pres-
ence or absence of 1 nmol/L insulin. Interestingly, whereas insulin was protective against I/R (30 min no ﬂow is-
chemia and 45 min reperfusion), it completely abolished cardioprotection by IPC in WT hearts but not in mice
lacking insulin receptors (IRs) in cardiomyocytes (CIRKO) or in all cardiac cells (TIRKO). The suppression of
IPC-mediated cardioprotection was mediated through downstream signaling to Akt and Gsk3β. In addition,
transgenic induction of Akt in the heart was sufﬁcient to abrogate IPC even when insulin was absent, further
conﬁrming the involvement of Akt in insulin's suppression of cardioprotection by IPC. These data provide evi-
dence that excessive insulin signaling to Akt is detrimental for cardioprotection by IPC and could explain the fail-
ure of the diabetic myocardium to precondition.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The global incidence of diabetes mellitus is increasing with the esti-
mated number reaching 366 million worldwide by 2030. Cardiovascu-
lar disease is the major cause of mortality among patients with
diabetes, accounting for nearly 60–80% of the deaths [1,2]. Epidemiolog-
ical studies and clinical trials have clearly shown that both type 1 and
type 2 diabetic individuals are more prone to developing ischemic
heart disease, including acute myocardial infarction and post-infarct
complications. Moreover, mortality from acute myocardial infarction is
almost doubled in diabetic patients comparedwith nondiabetic individ-
uals [3,4]. Despite the burden of ischemic heart disease among diabetic
individuals, effective treatment is currently unavailable.gy, Metabolism and Diabetes,
Rm. 3410B, Salt Lake City, UT
1.
udina).
.Open access under CC BY-NC-ND liceIschemic preconditioning (IPC) is considered one of themost protec-
tivemechanisms known to reduce ischemic damage in humans and an-
imals [5–7]. IPC consists of subjecting the heart to brief cycles of
ischemia and reperfusion (I/R) prior to amore prolonged ischemic peri-
od [8]. Recently, post-conditioning, which consists of applying very brief
cycles of I/R in the early phase of reperfusion, has also been shown to
protect the heart, and this protocol can easily be applied in the clinical
setting. Similar to IPC, insulin and insulin-like growth factor 1 (IGF-1)
protect the heart from I/R injury as evidenced by their ability to reduce
infarct size when given prior to ischemia or at the reperfusion [9–11].
However, despite its cardioprotective property in animal studies, sever-
al clinical observations showed that insulin had either no effect orwors-
ened cardiovascular events in type 2 diabetic patients [12–14]. For
example, the UK Prospective Diabetes Study (UKPDS) showed that the
use of intensive glucose lowering therapywith insulin over 10 years re-
duced the frequency of micro-vascular endpoints but had minimal
effects on diabetes-related mortality or myocardial infarction [15]. Fur-
thermore, in a separate study by Mellbin et al. [16], post-hoc propor-
tional hazard regression analysis showed that although cardiovascular
mortality was not affected, the risk of nonfatal myocardial infarction
and stroke was 73% higher in patients who were on insulin therapy,nse.
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Fig. 1. Perfusion protocol. Male mice were perfused ex vivo using Langendorff perfusion
system. Hearts were allowed to stabilize for 20 min before contractile parameters were
measured (baseline) and then subjected to either an ischemia/reperfusion protocol
consisting of 30 min no ﬂow ischemia followed by 45 min reperfusion or preconditioned
by three cycles of 5 min no ﬂow ischemia followed by 5 min reperfusion each, before a
30 min no ﬂow ischemia followed by 45 min reperfusion. Insulin (1 nmol/L) was absent
or present during the entire protocol. Stab: stabilization; I/R: ischemia/reperfusion; IPC: is-
chemic preconditioning.
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whom insulin was newly started and in those randomly assigned to
insulin in the study. In addition, many investigations have now showed
that the failure to precondition the diabetic heart is not always associated
with reduced insulin signaling. Indeed, insulin-mediated signal trans-
duction to phosphoinositide 3-kinase (PI3K) and Akt is elevated in the
hearts of patients with type 2 diabetes and in obese diabetic ob/ob mice
[17,18]. Despite this activated insulin signaling pathway, cardioprotection
by ischemic post-conditioningwas not achieved in ob/obmice, suggesting
that chronic activation of insulin signaling is rather detrimental for
cardioprotection. Indeed, excessive insulin signaling exacerbated sys-
tolic dysfunction in mice subjected to pressure overload, an effect that
was prevented either by lowering hyperinsulinemia or by reducing in-
sulin signaling [19]. Therefore, the main objective of this study is to
determinewhether activation of insulin signaling prior to IPC is detrimen-
tal for cardioprotection and to investigate the mechanisms involved.
2. Methods
2.1. Animals
The investigation conforms to the Guide for the Care and Use of Labo-
ratory Animals published by the US National Institutes of Health (NIH
publication no. 85-23, revised 1996) andwas approved by the Institution-
al Animal Care andUse Committee of theUniversity of Utah.Male Ttr-Insr
−/− (TIRKO)mice (on a C57B6j background) and cardiomyocyte-speciﬁc
insulin receptor knockout (CIRKO) mice (mixed background), previously
described [20,21], and their respectivewild-type (WT) control micewere
used between 10 and 14 weeks of age. Mice harboring α-MHC-tTA and
Tet-myrAkt1 genes (Tet-off Akt transgenic: abbreviated as Akt TG), previ-
ously described [22], were fed 1 g/kg body weight doxycycline chow
(DOX) for 8 weeks before the chow was removed for 2 weeks to allow
cardiac-speciﬁc induction of the myrAkt1 transgene. Wild-type, Tet-
myrAkt1 TG and α-MHC-tTA TG mice were used as controls and were
all on a mixed background.
2.2. Heart perfusion
Mice were anesthetized by intra-peritoneal injection of 15 mg of
chloral hydrate, and the heart was rapidly excised and arrested in ice-
cold buffer. The aorta was then cannulated and retrogradely perfused
at constant pressure of 60 mm Hg with 37 °C Krebs buffer containing
(in mmol/L) NaCl 118, KCl 4.7, NaHCO3 25, MgSO4 1.2, KH2PO4 1.2,
and CaCl2 2, glucose 11, and gassedwith 95%O2 and 5%CO2. Left ventric-
ular pressurewasmonitored fromawater-ﬁlled balloon placed through
the left atrial appendage and connected to a Millar transducer (Millar
Instruments, Houston, TX). The balloon was inﬂated to achieve an
end-diastolic pressure of 7–10 mm Hg.
2.3. Perfusion protocols
Hearts from TIRKO, CIRKO, Akt TG and their corresponding WT mice
were allowed to stabilize for 20 min before basal hemodynamic parame-
ters and coronary ﬂow were recorded (baseline). Hearts were then
subjected to an ischemic preconditioning (IPC) protocol (Fig. 1) consisting
of three cycles of 5 min ischemia followed by 5 min reperfusion before
30 min no ﬂow ischemia followed by 45 min reperfusion during which
hemodynamic parameters and coronary ﬂowwere again recorded. Perfu-
sions were performed in the presence or absence of 1 nmol/L insulin
(human insulin 100 U/mL stock, Novolin, Novo Nordisk Inc. Princeton,
NJ), that was added to the perfusate and kept for the entire perfusion
protocol. In subsequent experiments, WT hearts were stabilized for
20 min before 30 min of noﬂow ischemiawas applied and then follow-
ed by45 min reperfusion (I/R group). Finally, someheartswere used for
glycogen assay and western-blotting was perfused with or withoutinsulin for 50 min or subjected to three cycles of IPC (5 min each) and
then snap-frozen for analysis.2.4. Infarct size measurement
Triphenyltetrazolium chloride (TTC) staining was used to assess
myocardial tissue viability and to determine myocardial infarct size.
Hearts were subjected to IPC as shown in Fig. 1 without the insertion
of the balloon. At the end of the 45 min reperfusion, hearts were per-
fused with 1% TTC in PBS, pH 7.4, at 37 °C for 5 min and then collected
and sectioned. The tissue slices were then incubated in 1% TTC in PBS,
pH 7.4, at 37 °C for 20 min. Tissues were ﬁxed in 10% PBS-buffered for-
malin overnight at 4 °C. Both sides of each TTC-stained tissue slice were
photographed and digital photographs were acquired. The infracted
area (unstained) was measured using the Image-Pro Plus software
package, version 5.0 (Media Cybernetics; Silver Springs, USA) and was
expressed as % of risk zone.2.5. Immuno-blotting analysis
Total proteins were extracted from hearts that were frozen either at
the endof the 45 min reperfusion period (full IPC protocol) or at the end
of the three cycles of IPC (prior to the30 min ischemia). Heartswere ini-
tially pulverized under liquid nitrogen and then homogenized with a
Polytron in sample buffer containing (in mmol/L) HEPES 30, pH 7.4, so-
dium pyrophosphate 50, sodium ﬂuoride 100, EDTA 1, and sodium
orthovanadate 10 supplemented with 1% Triton X-100 and protease in-
hibitor cocktail (Roche Diagnostics, Mannheim, Germany). Protein
concentration was measured using a Micro BCA reagent (Pierce, Rock-
ford, IL). Protein extracts were resolved by SDS-PAGE and electro-
transferred onto an Immobilon PVDF membrane (Millipore Corp.,
Bedford, MA). Membranes were probed with the following primary an-
tibodies: mouse anti-Akt1, rabbit anti-p-Akt (Ser 473) and rabbit anti-
p-Akt (Thr 308) (1/1000; 1/750; 1/1000 respectively, Cell Signaling
Technology Inc. Danvers, MA), mouse anti-Gsk3α/β and rabbit anti-
Phospho-Gsk3β (Ser 9) (1/1000 and 1/2000 respectively, Cell Signaling
Technology Inc., Danvers, MA), rabbit-anti LC3 (1/1000, Sigma-Aldrich,
St. Louis, MO), rabbit anti-p38MAPK, rabbit anti-Phosphop38MAPK, rab-
bit anti-MEK and rabbit anti-PhosphoMEK (1/1000, Cell Signaling Tech-
nology Inc., Danvers MA) and mouse anti-actin (1/1000, Sigma-Aldrich,
St. Louis, MO). Alexa Fluor anti-Rabbit 680 (Invitrogen, Carlsbad, CA)
and anti-mouse 800 (VWR International, West Chester, PA) were used
as secondary antibodies and ﬂuorescence was quantiﬁed using the LI-
COR Odyssey imager (LI-COR, Lincoln, NE).
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For glycogenmeasurements, three different sets of hearts from both
TIRKO andWTmicewere used (1) hearts thatwere perfused for 50 min
with or without 1 mmol/L insulin; (2) hearts that were subjected to
three cycles of IPC but no prolonged ischemia or reperfusion and
(3) hearts that were subjected to full I/R or IPC protocols in the absence
or presence of 1 nmol/L insulin as outlined in Fig. 1. At the end of each
perfusion protocol, hearts were snap-frozen in liquid nitrogen and
stored at −80 °C until further analysis. Total glycogen was measured
by acid extraction followed by enzymatic hydrolysis with amylo-α-
1,4-α-1,6-glucosidase and measurement of glucose as previously de-
scribed [23]. Total glycogen was expressed in μmol glucose/g wet tissue
weight.2.7. Metabolomic analysis
2.7.1. Extraction of metabolites
Only hearts that were perfused with full I/R or full IPC in the ab-
sence or presence of 1 nmol/L insulin were used. At the end of the
45 min reperfusion, hearts were snap-frozen in liquid nitrogen and
stored at −80 °C for further analysis. Frozen heart samples (~50 mg)
were homogenized in cold methanol (−20 °C) containing D4-succinate
as an internal standard at a ﬁnal concentration of 80% MeOH (aq) and
20% tissue homogenate. Samples were vortexed and incubated for 1 h
at−20 °C to precipitate protein. Following incubation, cell debris was
pelleted by centrifugation (14,000 g for 5 min at 4 °C) and the
supernatant reserved. A second extraction of the pellet was performed
by the addition of −20 °C MeHO (aq) to a ﬁnal concentration of 50%
MeOH (aq) and 50% tissue homogenate. Each sample was mixed by
vortex, incubated for 1 h at −20 °C, and centrifuged (14,000 g for
5 min at 4 °C) to remove cell debris. The two extracts were combined
and dried en vacuo.2.7.2. Gas chromatography–mass spectrometry (GC–MS) analysis
GC–MS analysis was performed with a Waters GCT Premier mass
spectrometer ﬁtted with an Agilent 6890 gas chromatograph and a
Gerstel MPS2 autosampler. Dried samples were suspended in 40 μL of
40 mg/mL O-methoxylamine hydrochloride (MOX) in pyridine and in-
cubated for 1 h at 30 °C. 25 μL of this solutionwas added to autosampler
vials, then 20 μL of N-methyl-N-trimethylsilyl triﬂuoroacetamide
(MSTFA) was added using the autosampler and incubated for
60 min at 37 °C with shaking. 1 μL of the sample was injected to
the gas chromatograph inlet in the split mode at a 10:1 split ratio
with the inlet temperature held at 250 °C. The gas chromatograph had
an initial temperature of 95 °C for 1 min followed by a 40 °C/min
ramp to 110 °C and a hold time of 2 min. This was followed by a
second 5 °C/min ramp to 250 °C, a third ramp to 350 °C, then a ﬁnal
hold time of 3 min. A 30 m Phenomenex-ZB5MSi column with a 5 m
long guard column was employed for chromatographic separation.
Data was collected using MassLynx 4.1 software (Waters). Known me-
tabolites were identiﬁed and their peak area was recorded using
QuanLynx. Data was transferred to an Excel ﬁle where each sample
was normalized to the internal standard D4-succinate.2.8. Statistical analysis
All values were expressed as means ± standard error of the mean
(SEM). Comparisons between two groups were evaluated by Student's
t-test. To compare results from more than two groups, a two-way
ANOVA followed by Bonferroni test was performed using GraphPad
Prism software, version 5 (GraphPad Software, Inc. La Jolla, CA). A p
value of less than 0.05 was considered statistically signiﬁcant.3. Results
3.1. Insulin suppressed cardioprotection by IPC in wild-type mice but not in
TIRKO mice
To determine the role of insulin receptors in cardioptotection, we
subjected TIRKO and wild-type (WT) hearts to I/R or IPC in the absence
or presence of 1 nmol/L insulin, present for the entire duration of I/R or
IPC protocol (Fig. 1). Percent (%) recovery of the left ventricular devel-
oped pressure (LVDP) and rate pressure product (RPP)was determined.
Consistent with previously published results showing that the presence
of insulin at the reperfusion protected rat hearts from I/R injury [10], we
demonstrated that the presence of insulin prior to ischemia and during
reperfusion protected WT hearts from ischemia. Thus, % recovery of
LVDP and RPP was signiﬁcantly (p b 0.05) elevated in WT hearts
subjected to I/R with insulin compared to WT hearts subjected to I/R
without insulin (Figs. 2A, B). In contrast, the protective effect of insulin
against I/R was lost in TIRKO hearts, consistent with absent insulin sig-
naling. Of note, the absence of insulin receptors in TIRKO hearts did
not exacerbate ischemic injury relative to WT hearts perfused without
insulin. Three cycles of IPC in the absence of insulin protected WT
and TIRKO hearts from ischemia as evidenced by the increase in %
recovery of LVDP and RPP compared to the I/R without insulin
(Figs. 2A, B). Interestingly, when insulin was present for the entire
IPC protocol, cardioprotection was lost in WT hearts as indicated by
poor recovery of contractile function. In contrast, IPC protected TIRKO
hearts from ischemia despite the presence of insulin, indicating that ab-
olition of IPC by insulin requires the presence of insulin receptors in the
heart.
To determine the effect of insulin on infarct size, a separate group of
WTand TIRKOheartswere subjected to I/R or IPC in the absence or pres-
ence of 1 nmol/L insulin as outlined in Fig. 1, without insertion of the
balloon. Consistent with the functional data, infarct size, expressed as
% of risk zone,was signiﬁcantly (p b 0.05) bigger inWThearts subjected
to I/R without insulin or to IPC with insulin (Fig. 2C). In contrast, while
TIRKO hearts subjected to I/R were susceptible to infarction, IPCwas ex-
tremely efﬁcient in reducing infarct size in these animals independently
of insulin (Fig. 2C).
3.2. Insulin's suppression of IPC-mediated cardioprotection requires
cardiomyocyte insulin receptors
Having demonstrated that insulin abolished cardioprotection by IPC
and that this effect was abolished in hearts lacking the insulin receptors
(IRs) in the entire heart, we next sought to determine whether this ef-
fect was mediated via cardiomyocyte IRs. To achieve this goal, we
subjected hearts that lack IRs speciﬁcally in cardiomyocytes (isolated
from CIRKO mice) to I/R or IPC in the absence or presence of 1 nmol/L
insulin and measured functional recovery and infarct size. Similar to
TIRKO mice, CIRKO mice exhibited reduced heart size (Table 1),
conﬁrming the previously known role of insulin signaling in cardiac
growth regulation [21]. Independently of the background strain, insulin
protectedwild-type hearts from I/R as evidenced by enhanced function-
al recovery of LVDP and RPP and reduced infarct size (Figs. 3A, B). How-
ever, the beneﬁcial effect of insulin on functional recovery and infarct
size reduction after I/Rwas completely abolished in CIRKOmice. Similar
to results obtained in TIRKO mice, insulin suppressed IPC in WT mice
(different background strains) as evidenced by worse functional recov-
ery and bigger infarct size after ischemia. In contrast, IPC protected the
heart from ischemic injury in CIRKOmicedespite the presence of insulin
during the perfusion protocol (Figs. 3A, B). Thus insulin's suppression of
IPCwasmediated via cardiomyocyte IRs because CIRKO hearts were re-
fractory to insulin's abolition of IPC as suggested by their enhanced
functional recovery when insulin was present. It is important to note
that cardiac function at baseline as assessed by echocardiography is in-
distinguishable between TIRKO, CIRKO and their respectiveWT controls
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Fig. 2. Insulin protected against I/R and abolished cardioprotection by IPC in WT but not in TIRKO hearts. Hearts were isolated from mice lacking insulin receptors in the entire heart
(TIRKO) and their corresponding WT controls were subjected to I/R or IPC in the absence or presence of 1 nmol/L insulin. Contractile parameters were recorded at the end of the stabili-
zation period (baseline) and 10 min before the end of the reperfusion and are expressed as % from baseline values. (A) % recovery of the left ventricular developed pressure (LVDP); (B) %
recovery of rate pressure product (RPP) and (C) infarct size expressed as % of risk zone in TIRKO and their correspondingWT controls. Data aremean ± SEM (n = 3mice per group for I/R
and n = 7–9 mice per group for IPC). ⁎p b 0.05; ⁎⁎p b 0.005 versus WT perfused under the same condition; # p b 0.05; ##p b 0.005 versus (−insulin) within the same genotype.
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to IPC in the absence of insulin were similar to their controls, excluding
the possibility of additional protective mechanisms related to the ab-
sence of IRs in the heart.
3.3. Insulin's abolition of IPC occurs despite elevated Akt phosphorylation
Cardioprotection by insulin was previously shown to involve
downstream signaling molecules such as phosphatidylinositol 3-
kinase (PI3K), protein kinase B (PKB or Akt) and glycogen synthase
3β (Gsk3β) [10,24,25]. To explore whether insulin's effect on IPC re-
quired the activation of downstream signaling to Akt and Gsk3β, we
ﬁrst measured Akt (Ser473) and Gsk3β (Ser9) phosphorylation atTable 1
Morphometric parameters of TIRKO and CIRKO mice and their corresponding wild-type
controls.
WT TIRKO WT CIRKO
N 14 17 9 8
BW (g) 26.9 ± 0.5 27.2 ± 1 31.7 ± 1.1 34.7 ± 2.3
HW (mg) 173.3 ± 4.6 149.6 ± 5⁎⁎ 171.3 ± 7.4 146.1 ± 7.5
HW/BW (mg/g) 6.5 ± 0.2 5.5 ± 0.1⁎⁎ 5.4 ± 0.1 4.2 ± 0.12⁎⁎
BW: body weight; HW: heart weight; HW/BW: heart weight/body weight ratio. Data are
mean ± STE.
⁎⁎ p b 0.005 versus WT of the same strain.the end of the 45 min perfusion in TIRKO, CIRKO and their corre-
sponding WT hearts subjected to I/R or IPC in the absence or pres-
ence of 1 nmol/L insulin. Second, we determined whether insulin-
mediated activation of downstream signaling occurred prior to
ischemia by measuring both Akt (Ser473) and Gsk3β (Ser9) phos-
phorylation at the end of the three cycles of IPC. As expected, Akt
(Ser473) and Gsk3β (Ser9) phosphorylation at the end of the
reperfusion was signiﬁcantly (p b 0.005) enhanced in WT hearts
subjected to I/R in the presence of insulin compared to WT hearts
subjected to I/R without insulin (Fig. 4). The effect of insulin on the
phosphorylation of these two downstream effectors of insulin sig-
naling was abolished in TIRKO hearts (Fig. 4). Similarly, while insulin
was able to enhance Akt phosphorylation on Ser473 in WT hearts, it
failed to do so in CIRKO hearts (Fig. 1S). Interestingly, when compared
to I/R, IPC attenuated Akt and Gsk3β phosphorylation independently of
insulin. However, WT hearts subjected to IPC with insulin still exhibit
higher phosphoAkt/total Akt and phosphoGsk3β/total Gsk3β ratios
compared to WT hearts subjected to IPC without insulin (Figs. 4, 1S).
When applied prior to 30 min ischemia, insulin phosphorylated Akt
and Gsk3β inWT hearts but not in TIRKO and CIRKO hearts respectively
(Fig. 2S). However, although signiﬁcant (p b 0.05), this effect of insulin
on downstream effectors was less pronounced compared to WT hearts
examined at the end of the reperfusion. Taken together, these results
suggest that insulin's activation of downstream signaling is involved in
its suppression of cardioprotection by IPC.
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Fig. 3. Insulin's abolition of contractile recovery is mediated through cardiomyocyte insulin receptors. Hearts isolated from mice lacking insulin receptors speciﬁcally in cardiomyocytes
(CIRKO) and their corresponding WT controls were subjected to I/R or IPC in the absence or presence of 1 nmol/L insulin during the entire perfusion protocol. (A): % recovery of LVDP;
(B): % recovery of RPP and (C) infarct size in CIRKO mice respectively and their corresponding WT controls subjected to I/R or IPC in the absence or presence of 1 nmol/L insulin. Data
are mean ± SEM (n = 3–6 mice per group for I/R and n = 7–8 mice per group for IPC). ⁎p b 0.05; ⁎⁎p b 0.005 versus WT perfused under the same condition; # p b 0.05; ##p b 0.005
versus (−insulin) within the same genotype.
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To further investigate the involvement of Akt in mediating insulin's
effect on IPC, we used animals with 2 weeks induction of an activated
form of Akt in the heart. As shown in Figs. 5A–D, withdrawal of the
DOX chow for two weeks resulted in small but signiﬁcant increase in
Akt signaling and one of its downstream targets S6 as evidenced by el-
evated phosphorylated Akt (Ser473 or Thr308)/total Akt and phosphor-
ylated S6 (Ser253/236)/total S6 ratios. It is worth noting that total Akt
was increased by 15% (p = 0.06) in Akt TG hearts compared to WT
hearts, which was associated with a modest but signiﬁcant 6% increase
in heart weight (Fig. 5E) and heart weight/body weight ratio (Fig. 5F),
consistent with the previously known role of Akt in promoting cardiac
growth [26]. The presence of insulin resulted in an equivalent increase
in phosphoAkt/total Akt (~5 fold) and phospho S6/total S6 (~2 fold) ra-
tios respectively in WT and Akt TG (Fig. 5A). When Akt TG mice and
their littermate controls were subjected to IPC in the absence of insulin,
Akt TG hearts exhibited signiﬁcantly (p b 0.05) lower recovery of LVDP
compared to their control hearts perfused under the same conditions.
Furthermore and similar to control hearts perfused with insulin, % recov-
ery of LVDP and RPPwas reduced in Akt TGhearts (Figs. 5G andH). Taken
together, these data suggest that similar to the effect of insulin, short-term
activation of Akt1 in the heart abolished cardioprotection by IPC.3.5. Insulin's suppression of IPC does not involve MAP kinase pathway
In addition to Akt activation, we investigated the effect of insulin on
MAP kinase pathway. As shown in Figs. 6A–C, MAP kinase pathway, as
measured by thephosphorylation of p38MAPK or its downstreamtarget
MEK, was not modiﬁed by insulin in WT hearts. By contrast, we ob-
served a small but signiﬁcant (p b 0.005) increase in the ratio of phos-
phorylated p38MAPK/total p38MAPK in Akt TG hearts subjected to IPC
in the presence of insulin (Fig. 6B). However, this elevation did not
translate into the activation of its downstream target MEK (Fig. 6C).
3.6. Insulin's suppression of IPC is associated with less glycogen depletion
and more lactate production at the reperfusion
To evaluate the involvement ofmetabolic regulation by insulin in I/R
and IPC, we ﬁrst measured pre-ischemic cardiac glycogen content in
TIRKO hearts and their WT controls before ischemia. As shown in
Fig. 7A, insulin increased glycogen content in WT hearts but not in
TIRKO hearts. When both TIRKO and WT hearts were subjected to the
IPC stimulus, glycogen levels dropped signiﬁcantly (Fig. 7B). However,
insulin was able to signiﬁcantly enhance glycogen content by 37% in
WT hearts. Interestingly, after IPC stimulus, glycogen levels were high
in TIRKO hearts independently of insulin (Fig. 7B). Next, we measured
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hearts at the end of the 45 min reperfusion. As shown in Fig. 7C and
consistent with higher Gsk3β phosphorylation (Fig. 4C), WT hearts
subjected to I/R in the presence of insulin had 58% (p b 0.05) more gly-
cogen compared toWT hearts subjected to I/R without insulin. Similar-
ly, the combination of insulin with IPC inWT hearts increased glycogen
content by 3.8 fold (p = 0.08) compared to IPC without insulin
(Fig. 7C). In the other hand, lactic acid trended higher inWTI/R (+insu-
lin) compared toWTI/Rwithout insulin (Fig. 7D). By contrast, therewas
a modest increase in lactic acid in WTIPC (+insulin) compared to
WTIPC (− insulin) that did not reach statistical signiﬁcance (Fig. 7D).
It is worth noting that lactic acid levels were overall reduced within
the IPC groups compared to the I/R groups independently of the
genotype.
4. Discussion
This study was designed to determine the effect of insulin on ische-
mic preconditioning (IPC)-induced cardioprotection in mice. The major
results of this work are: (1) insulin suppressed functional recovery and
enhanced infarct size in wild-type mice subjected to IPC; (2) insulin's
abolition of IPC required the presence of cardiomyocyte insulin recep-
tors (IRs); and (3) the effect of insulin on cardioprotection by IPC is me-
diated through downstream signals to Akt but is independent of MAPK
signaling. Taken together, these ﬁndings demonstrate for the ﬁrst time
that persistent activation of Akt signaling by insulin is detrimental to
cardioprotection by IPC,whichmay explain in part the failure to precon-
dition the diabetic heart.4.1. Insulin suppressed IPC-mediated cardioprotection
IPC is a potent cardioprotective phenomenon that has been shown to
limit infarct size in dogs [8] and post-conditioning with repetitive I/R cy-
cles at the onset of reperfusion is as effective as IPC in protecting the
heart from a prolonged ischemic insult [27], which could be of great rel-
evance in the clinical setting. Similar to IPC andpost-conditioning, insulin
was shown to protect the heart from ischemic injurywhen administered
at the onset of reperfusion [10]. However, the effect of insulin on IPC has
never been explored before and could be of great importance for the clin-
ical utility of IPC or post-conditioning in patients with type 2 diabetes,
who most often exhibit hyperinsulinemia. In addition, although it is
still debated, several studies found that the diabetic heart is refractory
to cardioprotection by IPC or required a greater IPC stimulus to achieve
this protection [24,28–34] and that this resistance to IPC was mainly re-
lated to impaired PI3K–Akt signaling [24,35]. However, recent studies
have clearly challenged this idea by showing that instead of reduced in-
sulin signaling, PI3K–Akt signaling is rather enhanced in the hearts of
type 2 diabetic humans and animals [17,18]. Thus, we hypothesized
that insulin's activation of PI3K–Akt signaling prior to IPC could be detri-
mental to cardioprotection. Using a combination of pharmacologic and
genetic approaches, we demonstrated that insulin administered prior
to IPC abolished its cardioprotection in Langendorff-perfused mouse
heart. Thiswas evidencedbyworse functional recovery and increased in-
farct size inWT hearts subjected to IPC in the presence of 1 nmol/L insu-
lin. Although this is the ﬁrst study to directly assess the acute effect of
insulin on IPC, Drenger et al. [36] showed that correction of hyperglyce-
mia in streptozotocin-induced diabetic rats using insulin not only
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conditioning. Similarly, post-conditioning failed to protect the hearts of
obese and diabetic ob/ob mice despite enhanced basal insulin signaling
to Akt [17]. By contrast, our data are not supported by a prior study on
isolated human right atrial trabeculae obtained from patients taking in-
sulin and inwhich IPCwas shown to be effective in recovering developed
force [37]. This could be due in part to differences in the responses of
right atrial tissue versus whole heart to the IPC stimulus or to the exper-
imental protocol of IPC (hypoxic, glucose-free buffer with pacing versus
Langendorff-perfused heart with 11 mmol/L glucose and no pacing).
4.2. Insulin's abolition of IPC required the presence of cardiomyocyte IRs
Wenext sought to examine the involvement of the insulin receptors
(IRs) inmediating insulin's suppression of IPC and asked whether IRs of
speciﬁc cell types within the heart were responsible for this effect. We
used mice with either a complete ablation of IRs in the heart (TIRKO)
or with cardiomyocyte-speciﬁc deletion of IRs (CIRKO) and showed
that the negative effect of insulin on IPC required the presence of IRs
in cardiomyocytes as CIRKO mice exhibited the same cardioprotection
by IPC in the presence of insulin as TIRKO mice (Figs. 2 and 3). Impor-
tantly, our data demonstrated that the efﬁcacy of IPC to reduce infarct
size was actually potentiated when IRs are absent in the hearts asevidenced by reduced infarct size in TIRKO and CIRKO hearts subjected
to IPC in the absence of insulin (Figs. 2C and 3C). These results on func-
tional recovery and infarct size limitation in CIRKO mice are unique to
the IPC stimulus and contrast with previous ﬁndings showing that func-
tional recovery after myocardial infarction (induced by coronary artery
ligation) in CIRKO mice was impaired [38]. The failure to protect the
CIRKO heart from myocardial infarction was attributed to limited sub-
strate utilization and mitochondrial dysfunction. However, in the con-
text of IPC, the lack of cardiomyocyte IRs might be beneﬁcial.
4.3. Insulin's suppression of IPC requires downstream activation of Akt and
GsK3β
After establishing the involvement of IRs in mediating insulin's abo-
lition of cardioprotection by IPC,we next examined downstream signal-
ing to Akt and Gsk3β in TIRKO and CIRKO hearts subjected to I/R or IPC
in the absence or presence of insulin. Whether examined at the end of
reperfusion or at the end of the three IPC cycles, acute insulin treatment
induced Akt phosphorylation on Ser473 and Gsk3β phosphorylation on
Ser9 in hearts of TIRKO and CIRKO controls (Figs. 4, 1S and 2S). Howev-
er, the fold induction of Akt phosphorylation was much higher when
examined at the end of the reperfusion, suggesting that insulin's aboli-
tion of IPC-mediated cardioprotection may have occurred during the
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in the absence of IPC is believed to be mainly mediated during early re-
perfusion [10,39]. Downstreamof Akt, phosphorylation and inactivationIn
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[42]. Our results demonstrated that despite increased Gsk3β phosphor-
ylation and inhibition by insulin, the heart could no longer be protected
by this protocol, suggesting the existence of Gsk3β-independent mech-
anisms mediating the insulin's effect on IPC.
4.4. Moderate induction of Akt in the heart abolished cardioptotection by
IPC
To directly assess the role of Akt activation in cardioprotection by IPC,
we used hearts with inducible activation of Akt (myrAkt 1) [22]. We
hypothesized that if insulin-abolished cardioprotection was associated
with downstream activation of Akt signaling, then Akt TG hearts, with
moderate expressionofmyrAkt1, shouldbe refractory to cardioprotection
by IPC even in the absence of insulin. As detailed in the Methods section,
we induced the myrAkt transgene for two weeks, which resulted in a
modest but signiﬁcant increase in Akt expression and one of its down-
stream targets S6 (Figs. 5B–D) and enhanced cardiac growth. The induc-
tion of Akt and its downstream target S6 were not inﬂuenced by the IPC
stimulus as equivalent changes in their expression were also observed
in these animals at baseline when the hearts were not perfused [43].
As predicted, Akt1 induction in the heart was sufﬁcient to abrogate
IPC-mediated cardioprotection as evidenced by the poor functional re-
covery of the Akt TG hearts (Figs. 5G and H) in the absence of insulin.
The mechanisms by which activation of Akt abolished IPC-mediated
cardioprotection have not been fully investigated in the present study
but could involve the inhibition of glucose uptake via feedback impair-
ment of insulin receptor substrate (IRS)1/2. Although, we did not assess
IRS 1/2 expression or glucose uptake inWT and Akt TG hearts subjected
to IPC, a recent study showed that moderate induction of myrAkt1 in
the heart (equivalent to ours) did not impair insulin-mediated IRS 1/2
but reduced glucose uptake [43]. It should be noted however that our
data on Akt TG are not in agreement with a recent study by Kunuthur
et al. [44] showing that mice deﬁcient in Akt1 were resistant to infarct
limitation by IPC. However, it should be noted that in this study, Akt
phosphorylation on Thr308 was enhanced when normalized to total
Akt, which could explain their resistance to IPC. This increase in Akt
phosphorylation on Thr308 is probably caused by Akt2 activation.
4.5. Metabolic changes associated with insulin's abrogation of IPC
To explore the involvement of metabolic regulation in insulin's sup-
pression of IPC, we ﬁrst assessed glycogen content in TIRKO and WT
hearts at different time points of perfusion. Next, we performed a
metabolomic analysis of key metabolites using GC–MS. When glycogen
was measured before ischemia and in the absence of the IPC stimulus,
insulin increased glycogen synthesis in WT but not in TIRKO hearts
(Fig. 7A). This could be due to enhanced Gsk3β phosphorylation on ser-
ine 9, leading to less inactivationof glycogen synthase as previously sug-
gested [45]. Interestingly, TIRKO hearts exhibited less glycogen content
compared toWT hearts independently of insulin, which could be due to
higher glycogen breakdown. Our results contrast prior report showing
that glycogen depletion prior to ischemia is beneﬁcial for functional re-
covery after no ﬂow ischemia [46], which is mainly due to less lactate
accumulation during ischemia and thus less cellular acidosis. In the
present study, we did notmeasure lactate levels at the onset of ischemia
but at the end of the 45 min reperfusion and found that insulin did not
signiﬁcantly enhance lactate levels in WT hearts despite higher glyco-
gen content. This could be related to stimulation of glucose oxidation
by insulin and reduced anaerobic glycolysis. One other possibility
could be that the beneﬁcial effect of insulin on functional recovery and
infarct size is independent of insulin's effect on glycogen or lactate. In-
deed, Jonassen et al. [10] demonstrated that the protective effect of in-
sulin on I/R is independent of glucose presence at the reperfusion
because the use of pyruvate in the reperfusion instead of glucose did
not negate insulin-mediated cardioprotection. Therefore, the authorsconcluded that cardioprotection by insulin is mediated via Akt and
p70S6 kinase but does not involve insulin-stimulated glucose uptake.
Compared to control perfusion, three cycles of IPC signiﬁcantly reduced
glycogen content in the heart independently of the genotype (Fig. 7B).
This observation is supported by prior studies highlighting glycogen de-
pletion as one of the mechanisms by which IPC protects the heart
[47,48]. Despite glycogen depletion by the IPC stimulus, insulin induced
a modest but signiﬁcant (p b 0.05) increase in glycogen content in WT
hearts, but whether this increase is causal for poor functional recovery
remains to be determined. When glycogen and lactate were examined
at the reperfusion, we also observed a higher glycogen content in WT
hearts perfused in the presence of insulin. Interestingly, although glyco-
gen accumulation was similar between WT I/R (+insulin) and WTIPC
(+insulin), functional recovery was completely different, suggesting
that glycogen content does not correlate with functional recovery. Fur-
thermore, we analyzed several other metabolites in the heart at the end
of the 45 min reperfusion and showed that lactate was higher in the I/R
groups compared to the IPC groups and that tricarboxylic (TCA) cycle
intermediates such as pyruvate, malate and fumarate accumulated
more in the I/R groups compared to IPC groups (Fig. 3S). However, none
of these metabolites showed a signiﬁcant variation in the IPC group
with the exception of succinate, which was signiﬁcantly (p b 0.05) in-
creased in WTIPC (+insulin) compared to WTIPC (−insulin). Succinate
can be used by complex II of the electron transport chain, which can
lead to higher production of reactive oxygen species (ROS) [49], possibly
exacerbating cellular damage in this group. The exact mechanisms by
which these insulin-mediated metabolic changes affect functional recov-
ery after IPC required further investigations. Finally, other mechanisms
could explain the detrimental effect of insulin on IPC including inhibition
of autophagy, alteration of nitric oxide or calcium signaling,modulation of
the mitochondrial KATP channel and perturbation of Na+/K+ ATPase
activity.
4.6. Study limitation
There are limitations in the present study. We used an ex-vivo per-
fusion system to assess cardioprotection by IPC, although this is an
established method to conduct such studies, it does not recapitulate
the in-vivo situation such as changes in the systemic milieu that could
affect cardioprotection. This is particularly true for TIRKO mice which
are known to be hyperinsulinemic between 20 and 25 weeks of age
[50]. In addition, only glucose (11 mmol/L) was used as substrate with-
out fatty acids, which are known to be the main substrate for the post-
ischemic heart [51]. Furthermore, only one dose of insulin was used in
this study (1 nmol/L), which is somewhat supraphysiologic, but was
aimed to mimic the hyperinsulinemic state observed in diabetes. In ad-
dition, signalingmolecules downstreamof Akt thatmediate insulin's ef-
fect on IPC have not yet been identiﬁed and could be the subject of
future investigations. Finally, lactate levels were only assessed at the
end of the 45 min reperfusion and not during ischemia.
5. Conclusions
The present study suggests that insulinmay inhibit cardioprotection
by IPC through downstream activation of PI3K–Akt signaling, which
could in part explain the resistance of the diabetic heart to
cardioprotection by IPC in the context of increased insulin signal-
ing. Additional work is needed to determine the mechanisms by
which insulin inhibits IPC-mediated cardioprotection and to exam-
ine whether reducing insulin signaling in the hearts of type 2 dia-
betic animals could sensitize their hearts to IPC.
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